ASX:CSLBiotechs
Is CSL’s Buy-back And New Pandemic Vaccine Deal Altering The Investment Case For CSL (ASX:CSL)?
CSL Limited has continued its on-market share buy-back program, repurchasing nearly 4 million shares, while its CSL Seqirus unit previously secured a contract to supply Canada with 15 million doses of cell-based adjuvanted pandemic influenza vaccine from its new Tullamarine facility.
Together, these capital management actions and the first international vaccine supply agreement from the Melbourne site underline CSL’s confidence in its operations and expanding global pandemic response...